GLP-1
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
<StructureSection size='340' side='right' scene='84/841095/Cv/1'> | <StructureSection size='340' side='right' scene='84/841095/Cv/1'> | ||
== Structure == | == Structure == | ||
| - | GLP-1 has an alpha-helical structure | + | GLP-1 has an <scene name='10/1067195/Cv1/1'>alpha-helical structure</scene> |
== Synthesis == | == Synthesis == | ||
| Line 10: | Line 10: | ||
== Binding to receptor == | == Binding to receptor == | ||
| + | GLP-1 binds to the extracellular side of the GPL-1 receptor, a G-protein coupled receptor. When <scene name='84/841095/Cv1/1'>bound to the receptor</scene>, GLP-1 acts as agonist resulting in cAMP production in the cell. | ||
== Consequences of receptor binding == | == Consequences of receptor binding == | ||
Revision as of 15:51, 7 December 2024
GLP-1, glucagon-like peptide, is a hormone involved in insulin regulation. It was discovered when researchers found that glucose in the digestive tract led to higher insulin levels than the same amount of glucose administered directly in the blood stream. GLP-1 is produced in specialized cells in the intestine and in the pancreas, is released into the blood and has effects on cells in the pancreas, in the brain, and in many other organs. The half-life of GLP-1 is on the order of minutes, so it exerts a short-term effect unless continuously produced.
| |||||||||||
